These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22906689)

  • 1. A novel process related impurity and forced degradation study of synthetic wogonin: development of a liquid chromatographic method for purity control.
    Xia Y; Wu C; Liu W; Feng F; Li Z
    J Pharm Biomed Anal; 2012 Dec; 71():168-72. PubMed ID: 22906689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and characterization of a potential process related impurity of phenazopyridine HCl by preparative HPLC followed by MS-MS and 2D-NMR spectroscopy.
    Rao RN; Maurya PK; Raju AN
    J Pharm Biomed Anal; 2009 Jul; 49(5):1287-91. PubMed ID: 19376664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Forced degradation and impurity profiling: recent trends in analytical perspectives.
    Jain D; Basniwal PK
    J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification, characterization and quantification of a new impurity in deferasirox active pharmaceutical ingredient by LC-ESI-QT/MS/MS.
    Thomas S; Chandra Joshi S; Vir D; Agarwal A; Rao RD; Sridhar I; Xavier CM; Mathela CS
    J Pharm Biomed Anal; 2012 Apr; 63():112-9. PubMed ID: 22361658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A validated stability-indicating LC method for acetazolamide in the presence of degradation products and its process-related impurities.
    Srinivasu P; Subbarao DV; Vegesna RV; Sudhakar Babu K
    J Pharm Biomed Anal; 2010 May; 52(1):142-8. PubMed ID: 20053517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification, synthesis, isolation and spectral characterization of potential impurities of montelukast sodium.
    Saravanan M; Siva Kumari K; Pratap Reddy P; Naidu MN; Moses Babu J; Srivastava AK; Lakshmi Kumar T; Chandra Sekhar BV; Satyanarayana B
    J Pharm Biomed Anal; 2008 Nov; 48(3):708-15. PubMed ID: 18755563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
    Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
    J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural elucidation of a process-related impurity in ezetimibe by LC/MS/MS and NMR.
    Raman B; Sharma BA; Butala R; Ghugare PD; Kumar A
    J Pharm Biomed Anal; 2010 May; 52(1):73-8. PubMed ID: 20079995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RP-LC Method Development and Validation for Dasatinib Forced Degradation Study: Isolation and Structural Characterization by NMR and HRMS.
    Kavitapu DR; Murty JNSRC; Maruthapillai A; Senadi GC; Mahapatra S
    J Chromatogr Sci; 2024 Apr; 62(4):347-355. PubMed ID: 37340779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and structural elucidation of an unknown impurity in carbamazepine active pharmaceutical ingredient by liquid chromatography-tandem mass spectrometry and semi-preparative chromatographic isolation.
    Thomas S; Mathela CS; Agarwal A; Paul SK
    J Pharm Biomed Anal; 2011 Sep; 56(2):423-8. PubMed ID: 21676571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levothyroxine sodium revisited: A wholistic structural elucidation approach of new impurities via HPLC-HRMS/MS, on-line H/D exchange, NMR spectroscopy and chemical synthesis.
    Ruggenthaler M; Grass J; Schuh W; Huber CG; Reischl RJ
    J Pharm Biomed Anal; 2017 Feb; 135():140-152. PubMed ID: 28024262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel UV degradation product of Ebastine: isolation and characterization using Q-TOF, NMR, IR and computational chemistry.
    Rapolu R; Pandey AK; Raju ChK; Ghosh K; Srinivas K; Awasthi A; Navalgund SG; Surendranath KV
    J Pharm Biomed Anal; 2015 Mar; 107():488-94. PubMed ID: 25679093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification, isolation and characterization of potential degradation product in risperidone tablets.
    Bharathi Ch; Chary DK; Kumar MS; Shankar R; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Jan; 46(1):165-9. PubMed ID: 17981421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification, isolation, characterization and response factor determination of process-related impurity in meprobamate drug substance.
    Karthikeyan K; Arularasu GT; Murali V; Pillai KC
    J Pharm Biomed Anal; 2011 Jan; 54(1):208-12. PubMed ID: 20727702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability-indicating HPLC method development and structural elucidation of novel degradation products in posaconazole injection by LC-TOF/MS, LC-MS/MS and NMR.
    Yang Y; Zhu X; Zhang F; Li W; Wu Y; Ding L
    J Pharm Biomed Anal; 2016 Jun; 125():165-77. PubMed ID: 27023129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of a novel acid degradation impurity of Amlodipine Besylate using Q-TOF, NMR, IR and single crystal X-ray.
    Rapolu R; Raju ChK; Srinivas K; Awasthi A; Navalgund SG; Surendranath KV
    J Pharm Biomed Anal; 2014 Oct; 99():59-66. PubMed ID: 25072842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural identification and characterization of impurities in ceftizoxime sodium.
    Bharathi Ch; Prasad ChS; Bharathi DV; Shankar R; Rao VJ; Dandala R; Naidu A
    J Pharm Biomed Anal; 2007 Jan; 43(2):733-40. PubMed ID: 16950586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A validated stability-indicating RP-HPLC method for levofloxacin in the presence of degradation products, its process related impurities and identification of oxidative degradant.
    Lalitha Devi M; Chandrasekhar KB
    J Pharm Biomed Anal; 2009 Dec; 50(5):710-7. PubMed ID: 19632800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and relative response factor determination of process related impurity in Naproxen by nuclear magnetic resonance spectroscopy.
    Iqbal MY; Rao KM; Sridhar G; Raju PP; Deshpande GR; Babu JM
    J Pharm Biomed Anal; 2011 Nov; 56(3):484-90. PubMed ID: 21782369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical practical aspects in the application of liquid chromatography-mass spectrometric studies for the characterization of impurities and degradation products.
    Narayanam M; Handa T; Sharma P; Jhajra S; Muthe PK; Dappili PK; Shah RP; Singh S
    J Pharm Biomed Anal; 2014 Jan; 87():191-217. PubMed ID: 23706957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.